Cytokinetics, Incorporated, together with The Mended Hearts and WomenHeart: The National Coalition for Women with Heart Disease, announced the launch of ENACT: Empower, Navigate, Activate for Clinical Trials, an initiative designed to champion greater awareness and engagement in cardiovascular clinical trials by reducing barriers, increasing support and empowering patients in groups historically underrepresented in clinical research. The goal of ENACT is to provide greater education to patients with cardiovascular diseases participating in clinical trials.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics, The Mended Hearts, Inc. and WomenHeart Announce Launch of New Initiative to Increase Engagement in Cardiovascular Clinical Trials
- Cytokinetics Reports Fourth Quarter 2023 Financial Results
- Is CYTK a Buy, Before Earnings?
- Cytokinetics to Announce Fourth Quarter Results on February 27, 2024
- Cytokinetics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference